BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sandhaus RA, Turino G, Brantly ML, Campos M, Cross CE, Goodman K, Hogarth DK, Knight SL, Stocks JM, Stoller JK, Strange C, Teckman J. The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult. Chronic Obstr Pulm Dis 2016;3:668-82. [PMID: 28848891 DOI: 10.15326/jcopdf.3.3.2015.0182] [Cited by in Crossref: 40] [Cited by in F6Publishing: 57] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Dummer J, Dobler CC, Holmes M, Chambers D, Yang IA, Parkin L, Smith S, Wark P, Dev A, Hodge S, Dabscheck E, Gooi J, Samuel S, Knowles S, Holland AE. Diagnosis and treatment of lung disease associated with alpha one-antitrypsin deficiency: A position statement from the Thoracic Society of Australia and New Zealand. Respirology 2020;25:321-35. [PMID: 32030868 DOI: 10.1111/resp.13774] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Pye A, Turner AM. Experimental and investigational drugs for the treatment of alpha-1 antitrypsin deficiency. Expert Opin Investig Drugs 2019;28:891-902. [PMID: 31550938 DOI: 10.1080/13543784.2019.1672656] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
3 Sandhaus R, Strange C, Stone G, Runken MC, Blanchette CM, Howden R. Comorbidity Associations with AATD Among Commercially Insured and Medicare Beneficiaries with COPD in the US. Int J Chron Obstruct Pulmon Dis 2020;15:2389-97. [PMID: 33116454 DOI: 10.2147/COPD.S263297] [Reference Citation Analysis]
4 Barjaktarevic I, Miravitlles M. Alpha-1 antitrypsin (AAT) augmentation therapy in individuals with the PI*MZ genotype: a pro/con debate on a working hypothesis. BMC Pulm Med 2021;21:99. [PMID: 33757485 DOI: 10.1186/s12890-021-01466-x] [Reference Citation Analysis]
5 Tumpara S, Martinez-Delgado B, Gomez-Mariano G, Liu B, DeLuca DS, Korenbaum E, Jonigk D, Jugert F, Wurm FM, Wurm MJ, Welte T, Janciauskiene S. The Delivery of α1-Antitrypsin Therapy Through Transepidermal Route: Worthwhile to Explore. Front Pharmacol 2020;11:983. [PMID: 32719598 DOI: 10.3389/fphar.2020.00983] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
6 Hersh CP, Campbell EJ, Scott LR, Raby BA. Alpha-1 Antitrypsin Deficiency as an Incidental Finding in Clinical Genetic Testing. Am J Respir Crit Care Med 2019;199:246-8. [PMID: 30359090 DOI: 10.1164/rccm.201809-1679LE] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Hendricks-Sturrup RM, Linsky A, Lu CY, Vassy JL. Genomic testing is best integrated into clinical practice when it is actionable. Per Med 2020;17:5-8. [PMID: 31795838 DOI: 10.2217/pme-2019-0106] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
8 Mostafavi B, Diaz S, Piitulainen E, Stoel BC, Wollmer P, Tanash HA. Lung function and CT lung densitometry in 37- to 39-year-old individuals with alpha-1-antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis 2018;13:3689-98. [PMID: 30510411 DOI: 10.2147/COPD.S167497] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
9 Hersh CP. Pharmacogenomics of chronic obstructive pulmonary disease. Expert Rev Respir Med 2019;13:459-70. [PMID: 30925849 DOI: 10.1080/17476348.2019.1601559] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
10 Lopes AP, Mineiro MA, Costa F, Gomes J, Santos C, Antunes C, Maia D, Melo R, Canotilho M, Magalhães E, Vicente I, Valente C, Gonçalves BG, Conde B, Guimarães C, Sousa C, Amado J, Brandão ME, Sucena M, Oliveira MJ, Seixas S, Teixeira V, Telo L. Portuguese consensus document for the management of alpha-1-antitrypsin deficiency. Pulmonology 2018;24 Suppl 1:1-21. [PMID: 30473034 DOI: 10.1016/j.pulmoe.2018.09.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
11 Padilla-Godínez FJ, Ramos-Acevedo R, Martínez-Becerril HA, Bernal-Conde LD, Garrido-Figueroa JF, Hiriart M, Hernández-López A, Argüero-Sánchez R, Callea F, Guerra-Crespo M. Protein Misfolding and Aggregation: The Relatedness between Parkinson's Disease and Hepatic Endoplasmic Reticulum Storage Disorders. Int J Mol Sci 2021;22:12467. [PMID: 34830348 DOI: 10.3390/ijms222212467] [Reference Citation Analysis]
12 Guan S, Darmstädter M, Xu C, Rosenecker J. In Vitro Investigations on Optimizing and Nebulization of IVT-mRNA Formulations for Potential Pulmonary-Based Alpha-1-Antitrypsin Deficiency Treatment. Pharmaceutics 2021;13:1281. [PMID: 34452241 DOI: 10.3390/pharmaceutics13081281] [Reference Citation Analysis]
13 Santos G, Turner AM. Alpha-1 antitrypsin deficiency: an update on clinical aspects of diagnosis and management. Fac Rev 2020;9:1. [PMID: 33659933 DOI: 10.12703/b/9-1] [Reference Citation Analysis]
14 Greulich T, Chlumsky J, Wencker M, Vit O, Fries M, Chung T, Shebl A, Vogelmeier C, Chapman KR, McElvaney NG; RAPID Trial Group. Safety of biweekly α1-antitrypsin treatment in the RAPID programme. Eur Respir J 2018;52:1800897. [PMID: 30237305 DOI: 10.1183/13993003.00897-2018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
15 Zamora MR, Ataya A. Lung and liver transplantation in patients with alpha-1 antitrypsin deficiency. Ther Adv Chronic Dis 2021;12_suppl:20406223211002988. [PMID: 34408830 DOI: 10.1177/20406223211002988] [Reference Citation Analysis]
16 Chapman KR, Chorostowska-Wynimko J, Koczulla AR, Ferrarotti I, McElvaney NG. Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications. Int J Chron Obstruct Pulmon Dis 2018;13:419-32. [PMID: 29430176 DOI: 10.2147/COPD.S149429] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
17 Miravitlles M, Dirksen A, Ferrarotti I, Koblizek V, Lange P, Mahadeva R, Mcelvaney NG, Parr D, Piitulainen E, Roche N, Stolk J, Thabut G, Turner A, Vogelmeier C, Stockley RA. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α 1 -antitrypsin deficiency. Eur Respir J 2017;50:1700610. [DOI: 10.1183/13993003.00610-2017] [Cited by in Crossref: 123] [Cited by in F6Publishing: 91] [Article Influence: 24.6] [Reference Citation Analysis]
18 Vuurberg NE, Van den Boom AL, Van den Heuvel MC, Klaase JM. Intrahepatic cholangiocarcinoma in a non-cirrhotic liver in a patient with homozygous ZZ alpha-1 antitrypsin deficiency. BMJ Case Rep 2021;14:e240077. [PMID: 33658218 DOI: 10.1136/bcr-2020-240077] [Reference Citation Analysis]
19 Mandru R, Zhou CY, Pauley R, Burkes RM. Considerations for and Mechanisms of Adjunct Therapy in COPD. J Clin Med 2021;10:1225. [PMID: 33809583 DOI: 10.3390/jcm10061225] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Brantly ML, Lascano JE, Shahmohammadi A. Intravenous Alpha-1 Antitrypsin Therapy for Alpha-1 Antitrypsin Deficiency: The Current State of the Evidence. Chronic Obstr Pulm Dis 2018;6:100-14. [PMID: 30775428 DOI: 10.15326/jcopdf.6.1.2017.0185] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
21 Horváth I, Canotilho M, Chlumský J, Chorostowska-Wynimko J, Corda L, Derom E, Ficker JH, Kneussl M, Miravitlles M, Sucena M, Thabut G, Turner AM, van 't Wout E, McElvaney NG. Diagnosis and management of α1-antitrypsin deficiency in Europe: an expert survey. ERJ Open Res 2019;5:00171-2018. [PMID: 30863774 DOI: 10.1183/23120541.00171-2018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
22 Barker AF, Campos MA, Brantly ML, Stocks JM, Sandhaus RA, Lee D, Steinmann K, Lin J, Sorrells S. Bioequivalence of a Liquid Formulation of Alpha1-Proteinase Inhibitor Compared with Prolastin®-C (Lyophilized Alpha1-PI) in Alpha1-Antitrypsin Deficiency. COPD 2017;14:590-6. [PMID: 28985109 DOI: 10.1080/15412555.2017.1376044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
23 Bellemare J, Gaudreault N, Valette K, Belmonte I, Nuñez A, Miravitlles M, Maltais F, Bossé Y. The Clinical Utility of Determining the Allelic Background of Mutations Causing Alpha-1 Antitrypsin Deficiency: The Case with the Null Variant Q0(Mattawa)/Q0(Ourém). Chronic Obstr Pulm Dis 2021;8. [PMID: 33150777 DOI: 10.15326/jcopdf.8.1.2020.0168] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Sieluk J, Slejko JF, Silverman H, Perfetto E, Mullins CD. Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States. Orphanet J Rare Dis 2020;15:260. [PMID: 32967697 DOI: 10.1186/s13023-020-01523-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Carreto L, Morrison M, Donovan J, Finch S, Tan GL, Fardon T, Wilson R, Furrie E, Loebinger M, Chalmers JD. Utility of routine screening for alpha-1 antitrypsin deficiency in patients with bronchiectasis. Thorax 2020;75:592-3. [PMID: 32303623 DOI: 10.1136/thoraxjnl-2019-214195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
26 Baranovski BM, Schuster R, Nisim O, Brami I, Lior Y, Lewis EC. Alpha-1 Antitrypsin Substitution for Extrapulmonary Conditions in Alpha-1 Antitrypsin Deficient Patients. Chronic Obstr Pulm Dis 2018;5:267-76. [PMID: 30723784 DOI: 10.15326/jcopdf.5.4.2017.0161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
27 Rigobello C, Baraldo S, Tinè M, Ferrarotti I, Corsico AG, Bazzan E, Turato G, Balestro E, Biondini D, Valle G, Saetta M, Cosio MG. Exome Sequencing Reveals Immune Genes as Susceptibility Modifiers in Individuals with α1-Antitrypsin Deficiency. Sci Rep 2019;9:13088. [PMID: 31511551 DOI: 10.1038/s41598-019-49409-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
28 Miskoff JA, Khan B, Chaudhri M, Phan H, Carson MP. Identifying Alpha-1 Antitrypsin Deficiency Based on Computed Tomography Evidence of Emphysema. Cureus 2019;11:e3971. [PMID: 30956923 DOI: 10.7759/cureus.3971] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Herth FJF, Sandhaus RA, Turner AM, Sucena M, Welte T, Greulich T. Alpha 1 Antitrypsin Therapy in Patients with Alpha 1 Antitrypsin Deficiency: Perspectives from a Registry Study and Practical Considerations for Self-Administration During the COVID-19 Pandemic. Int J Chron Obstruct Pulmon Dis 2021;16:2983-96. [PMID: 34754184 DOI: 10.2147/COPD.S325211] [Reference Citation Analysis]
30 Chan LW, Anahtar MN, Ong TH, Hern KE, Kunz RR, Bhatia SN. Engineering synthetic breath biomarkers for respiratory disease. Nat Nanotechnol 2020;15:792-800. [PMID: 32690884 DOI: 10.1038/s41565-020-0723-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
31 Soriano JB, Mahadeva R. α 1 -Antitrypsin deficiency: count me in please! Eur Respir J 2017;49:1601941. [DOI: 10.1183/13993003.01941-2016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
32 Luna Diaz LV, Iupe I, Zavala B, Balestrini KC, Guerrero A, Holt G, Calderon-Candelario R, Mirsaeidi M, Campos M. Improving adherence to alpha-1 antitrypsin deficiency screening guidelines using the pulmonary function laboratory. Int J Chron Obstruct Pulmon Dis 2017;12:2257-9. [PMID: 28814853 DOI: 10.2147/COPD.S143424] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
33 Annunziata A, Lanza M, Coppola A, Fiorentino G. Alpha-1 antitrypsin deficiency in the elderly: a case report. J Med Case Rep 2021;15:231. [PMID: 33966640 DOI: 10.1186/s13256-021-02847-w] [Reference Citation Analysis]
34 Evers G, Schulze AB, Thrull M, Hering JP, Schülke C, Wiewrodt R, Wittkowski H, Schmidt LH, Mohr M. Alpha-1 Antitrypsin Deficiency and Pulmonary Morbidity in Patients with Primary Immunodeficiency Disease: A Single-Center Experience. Can Respir J 2020;2020:4019608. [PMID: 32566054 DOI: 10.1155/2020/4019608] [Reference Citation Analysis]
35 Herrera EM, Joseph C, Brouwer ES, Gandhi V, Czorniak M. Alpha-1 Antitrypsin Deficiency-Associated Clinical Manifestations and Healthcare Resource Use in the United States. COPD 2021;18:315-24. [PMID: 34036848 DOI: 10.1080/15412555.2021.1917532] [Reference Citation Analysis]
36 Foil KE, Blanton MG, Sanders C, Kim J, Al Ashry HS, Kumbhare S, Strange C. Sequencing Alpha-1 MZ Individuals Shows Frequent Biallelic Mutations. Pulm Med 2018;2018:2836389. [PMID: 30254761 DOI: 10.1155/2018/2836389] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
37 Cheeney G, Pac LJ, Gopal P, Landis CS, Konnick EQ, Swanson PE, Greene DN, Lockwood CM, Westerhoff M. Increased Frequency of Heterozygous Alpha‐1‐Antitrypsin Deficiency in Liver Explants From Nonalcoholic Steatohepatitis Patients. Liver Transpl 2019;26:17-24. [DOI: 10.1002/lt.25652] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
38 Garudadri S, Woodruff PG. Targeting Chronic Obstructive Pulmonary Disease Phenotypes, Endotypes, and Biomarkers. Ann Am Thorac Soc 2018;15:S234-8. [PMID: 30758998 DOI: 10.1513/AnnalsATS.201808-533MG] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
39 Henao MP, Craig TJ. Recent advances in understanding and treating COPD related to α1-antitrypsin deficiency. Expert Rev Respir Med 2016;10:1281-94. [PMID: 27771979 DOI: 10.1080/17476348.2016.1249851] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
40 Schaefer B, Mandorfer M, Viveiros A, Finkenstedt A, Ferenci P, Schneeberger S, Tilg H, Zoller H. Heterozygosity for the alpha-1-antitrypsin Z allele in cirrhosis is associated with more advanced disease. Liver Transpl 2018;24:744-51. [PMID: 29573137 DOI: 10.1002/lt.25057] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
41 Boone PM, Scott RM, Marciniak SJ, Henske EP, Raby BA. The Genetics of Pneumothorax. Am J Respir Crit Care Med 2019;199:1344-57. [PMID: 30681372 DOI: 10.1164/rccm.201807-1212CI] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
42 Greulich T, Albert A, Cassel W, Boeselt T, Peychev E, Klemmer A, Ferreira F, Clarenbach C, Torres-Duran ML, Turner AM, Miravitlles M. Opinions and Attitudes of Pulmonologists About Augmentation Therapy in Patients with Alpha-1 Antitrypsin Deficiency. A Survey of the EARCO Group. Int J Chron Obstruct Pulmon Dis 2022;17:53-64. [PMID: 35023913 DOI: 10.2147/COPD.S346051] [Reference Citation Analysis]
43 Torres-Durán M, Lopez-Campos JL, Barrecheguren M, Miravitlles M, Martinez-Delgado B, Castillo S, Escribano A, Baloira A, Navarro-Garcia MM, Pellicer D, Bañuls L, Magallón M, Casas F, Dasí F. Alpha-1 antitrypsin deficiency: outstanding questions and future directions. Orphanet J Rare Dis 2018;13:114. [PMID: 29996870 DOI: 10.1186/s13023-018-0856-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 26] [Article Influence: 11.8] [Reference Citation Analysis]
44 Huang YT, Wencker M, Driehuys B. Imaging in alpha-1 antitrypsin deficiency: a window into the disease. Ther Adv Chronic Dis 2021;12_suppl:20406223211024523. [PMID: 34408834 DOI: 10.1177/20406223211024523] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
45 McElvaney GN, Sandhaus RA, Miravitlles M, Turino GM, Seersholm N, Wencker M, Stockley RA. Clinical considerations in individuals with α1-antitrypsin PI*SZ genotype. Eur Respir J 2020;55:1902410. [PMID: 32165400 DOI: 10.1183/13993003.02410-2019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
46 Barjaktarevic I, Campos M. Management of lung disease in alpha-1 antitrypsin deficiency: what we do and what we do not know. Ther Adv Chronic Dis 2021;12_suppl:20406223211010172. [PMID: 34408831 DOI: 10.1177/20406223211010172] [Reference Citation Analysis]
47 Craig TJ, Henao MP. Advances in managing COPD related to α1 -antitrypsin deficiency: An under-recognized genetic disorder. Allergy 2018;73:2110-21. [PMID: 29984428 DOI: 10.1111/all.13558] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
48 Attaway A, Majumdar U, Sandhaus RA, Nowacki AS, Stoller JK. An analysis of the degree of concordance among international guidelines regarding alpha-1 antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis 2019;14:2089-101. [PMID: 31564856 DOI: 10.2147/COPD.S208591] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
49 Arnhold J. The Dual Role of Myeloperoxidase in Immune Response. Int J Mol Sci 2020;21:E8057. [PMID: 33137905 DOI: 10.3390/ijms21218057] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
50 Tasch JJ, McLaughlan AT, Nasir AA. A Novel Approach to Screening for Alpha-1 Antitrypsin Deficiency: Inpatient Testing at a Teaching Institution. Chronic Obstr Pulm Dis 2018;5:106-10. [PMID: 30374448 DOI: 10.15326/jcopdf.5.2.2017.0170] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Connolly B, Isaacs C, Cheng L, Asrani KH, Subramanian RR. SERPINA1 mRNA as a Treatment for Alpha-1 Antitrypsin Deficiency. J Nucleic Acids 2018;2018:8247935. [PMID: 30009048 DOI: 10.1155/2018/8247935] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
52 López-Campos JL, Carrasco Hernandez L, Caballero Eraso C. Implications of a Change of Paradigm in Alpha1 Antitrypsin Deficiency Augmentation Therapy: From Biochemical to Clinical Efficacy. J Clin Med 2020;9:E2526. [PMID: 32764414 DOI: 10.3390/jcm9082526] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Foil KE. Variants of SERPINA1 and the increasing complexity of testing for alpha-1 antitrypsin deficiency. Ther Adv Chronic Dis 2021;12_suppl:20406223211015954. [PMID: 34408833 DOI: 10.1177/20406223211015954] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
54 Sieluk J, Levy J, Sandhaus RA, Silverman H, Holm KE, Mullins CD. Costs of Medical Care Among Augmentation Therapy Users and Non-Users with Alpha-1 Antitrypsin Deficiency in the United States. Chronic Obstr Pulm Dis 2018;6:6-16. [PMID: 30775420 DOI: 10.15326/jcopdf.6.1.2017.0187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
55 Gurevich S, Daya A, Da Silva C, Girard C, Rahaghi F. Improving Screening for Alpha-1 Antitrypsin Deficiency with Direct Testing in the Pulmonary Function Testing Laboratory. Chronic Obstr Pulm Dis 2021;8:190-7. [PMID: 33290644 DOI: 10.15326/jcopdf.2020.0179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Franciosi AN, Hobbs BD, McElvaney OJ, Molloy K, Hersh C, Clarke L, Gunaratnam C, Silverman EK, Carroll TP, McElvaney NG. Clarifying the Risk of Lung Disease in SZ Alpha-1 Antitrypsin Deficiency. Am J Respir Crit Care Med 2020;202:73-82. [PMID: 32197047 DOI: 10.1164/rccm.202002-0262OC] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
57 Jardim JR, Casas-Maldonado F, Fernandes FLA, Castellano MVCO, Torres-Durán M, Miravitlles M. Update on and future perspectives for the diagnosis of alpha-1 antitrypsin deficiency in Brazil. J Bras Pneumol 2021;47:e20200380. [PMID: 34076174 DOI: 10.36416/1806-3756/e20200380] [Reference Citation Analysis]
58 Hersh CP. Diagnosing alpha-1 antitrypsin deficiency: the first step in precision medicine. F1000Res 2017;6:2049. [PMID: 29225784 DOI: 10.12688/f1000research.12399.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
59 Joshi R, Ojha M, Lewis J, Fan Q, Monia B, Guo S, Varisco BM. Sex-specific differences in emphysema using a murine antisense oligonucleotide model of α-1 antitrypsin deficiency. Am J Physiol Lung Cell Mol Physiol 2019;316:L1165-73. [PMID: 31017014 DOI: 10.1152/ajplung.00502.2018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
60 Patel D, Teckman J. Liver disease with unknown etiology - have you ruled out alpha-1 antitrypsin deficiency? Ther Adv Chronic Dis 2021;12_suppl:2040622321995684. [PMID: 34408828 DOI: 10.1177/2040622321995684] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
61 Greulich T. Alpha-1-Antitrypsin Deficiency: Disease Management and Learning from Studies. COPD 2017;14:S8-S11. [PMID: 28306355 DOI: 10.1080/15412555.2017.1286166] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
62 Shen S, Sanchez ME, Blomenkamp K, Corcoran EM, Marco E, Yudkoff CJ, Jiang H, Teckman JH, Bumcrot D, Albright CF. Amelioration of Alpha-1 Antitrypsin Deficiency Diseases with Genome Editing in Transgenic Mice. Hum Gene Ther 2018;29:861-73. [PMID: 29641323 DOI: 10.1089/hum.2017.227] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
63 Kueppers F, Andrake MD, Xu Q, Dunbrack RL Jr, Kim J, Sanders CL. Protein modeling to assess the pathogenicity of rare variants of SERPINA1 in patients suspected of having Alpha 1 Antitrypsin Deficiency. BMC Med Genet 2019;20:125. [PMID: 31307431 DOI: 10.1186/s12881-019-0852-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
64 Ferrarotti I, Corsico AG, Stolk J, Ottaviani S, Fumagalli M, Janciauskiene S, Iadarola P. Advances in Identifying Urine/Serum Biomarkers in Alpha-1 Antitrypsin Deficiency for More Personalized Future Treatment Strategies. COPD 2017;14:56-65. [PMID: 27827549 DOI: 10.1080/15412555.2016.1241760] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
65 Ghosh AJ, Hobbs BD. Recent advancements in understanding the genetic involvement of alpha-1 antitrypsin deficiency associated lung disease: a look at future precision medicine approaches. Expert Rev Respir Med 2022;:1-10. [PMID: 35025710 DOI: 10.1080/17476348.2022.2027755] [Reference Citation Analysis]
66 Sanders CL, Ponte A, Kueppers F. The Effects of Inflammation on Alpha 1 Antitrypsin Levels in a National Screening Cohort. COPD: Journal of Chronic Obstructive Pulmonary Disease 2018;15:10-6. [DOI: 10.1080/15412555.2017.1401600] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]